Discover how next-generation kinase inhibitors are transforming clinical therapy byovercoming resistance and enhancing ...

One pharmacist drew attention to a massive pricing disparity on a key cancer drug, and that disparity may help to explain why ...

School of Pharmacy & Technology Management, SVKM’S NMIMS Deemed-to-be University, Shirpur, Maharashtra 425405, India ...

Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025• APEX trial enrollment in AdvSM patients complete; top-line results ...

Chris Cabell, MD MHS FACC Appointed President and Head of Research & Development ------ John Adams, PhD Appointed Chief Scientific ...

GSK completes acquisition of Boston-based, clinical-stage biopharma company, IDRx, Inc.

GSK plc (LSE/NYSE: GSK) today announced that it has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, ...

Out-of-pocket costs like deductibles and copays deter people with cancer from complying with treatment.This creates a ...

Gene-editing specialist Editas Medicine has halted development of its lead clinical programme for congenital eye disorders after it generated lacklustre results in a phase 1/2 trial. The ...

Dr. Carlos Correa discusses the impact of evergreening strategies on access to generic and biosimilar medicines globally.

GSK on Monday also said it has start the GBP2 billion buyback programme that it announced earlier this month, starting with an initial GBP700 million tranche.